Margaret K Offermann
Margaret K. Offermann, MD, PhD is a medical oncologist, tumor biologist, educator and executive with professional experience in academic, philanthropic and private sectors. She is the CEO of OncoSpherix, a preclinical stage cancer drug development company that is advancing a first-in-class family of small molecules that block the ability of cancer cells to adapt and spread from regions of low oxygen that results from growing faster than the blood supply.
Dr. Offermann previously served as Managing Partner of the Salutramed Group (a boutique C-level consulting group), Deputy National Vice President for Research at the American Cancer Society and Professor of Hematology and Oncology at Emory University, where she served as co-director of the MD, PhD training program, Associate Director of the Postgraduate Training Program in Hematology and Oncology and Associate Director of the Winship Cancer Institute.
She has served in executive roles with numerous non-profit organizations, including serving as President of the Federation of American Societies for Experimental Biology (FASEB), a federation of 30 non-profit research societies with over 130,000 members that advances biological science through collaborative advocacy for research policies that promote scientific progress and education.